

Record Quarter of Sales and Receipt of Additional Wholesale Products

Highlights:

- Incannex experiences a record quarter for patient acquisition and sales
- Cash receipts were \$695K in the September quarter of 2020
- Incannex receives 5500 units of Incannex branded *Cannagesia*, *Releafia*, *Nutralesic* and *Inflammex*
- Also receives hydroxychloroquine for IHL-675A combination drug with cannabidiol.

Clinical stage cannabinoid pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL, 'Incannex' or the 'Company'), is pleased to announce that it has earned \$695k in cash sales receipts from cannabinoid products in the three months to the 30th of September.

The September quarter is the first quarter in which the Company's cash revenues exclusively comprised the sale of cannabinoid products under the Australian special access scheme ('SAS'). IHL previously reported a record period of sales in the June quarter, however, that figure also included cash inflows from a dental devices business that was sold on the 30th of June.

Incannex also wishes to advise ASX that it has received an additional batch of 5500 medicinal cannabis oils. The batch of *Cannagesia*, *Releafia*, *Nutralesic*, *Inflammex* removes limitations on assisting patients seeking relief for epilepsy, inflammatory bowel disease, migraine, insomnia, opioid reduction, and arthritis, amongst other conditions.

Incannex has also recently received a batch of hydroxychloroquine compound (equivalent to approximately 5000 doses) to advance its research program into IHL-675A, a combination of Hydroxychloroquine and Cannabidiol for the alleviation of Sepsis Associated Acute Respiratory Distress Syndrome ('SAARDS').

On the 17th of July 2020, IHL reported positive results from its pre-clinical animal studies for the assessment of the components of IHL-675A against SAARDS. Incannex is currently undertaking *in vitro* studies to discover the optimal inflammation dampening response of the IHL-675A combination drug.

CEO and Managing Director of Incannex Healthcare, Mr Joel Latham, said; "the September 2020 quarter is the first quarter in which cannabinoid products were the sole contributor to our revenues. Therefore, I am delighted to report that our most significant quarter of cash sales has come immediately after Incannex finalised its transition into a pure play pharmaceutical development company.

Incannex's offering to shareholders is unique in that we have short and long-term pharmaceutical development goals. Our short-term goal is the provision of cGMP medicinal cannabis oils to our patients

For personal use only

under the Australian SAS. Our long-term goal is represented by our multifaceted pharmaceutical research program being undertaken to pursue patents, and FDA registration, in up to 4 therapeutic products. 3 of those research programs have commenced studies and we expect more study results to be received and shared with our investors imminently”.

IHL cannabinoid products are primarily sold under the Company’s product supply and distribution relationship with Cannvalate Pty Ltd, which is the largest network of cannabis medicine prescribers in Australia. The CEO of Cannvalate is Dr Sud Agarwal, who is also a Director and Chief Medical Officer of Incannex. Cannvalate and Dr Agarwal are major shareholders of IHL.

ENDS

The release of this announcement has been approved for issue by IHL’s Board of Directors. For further details on the announcement, interested parties should contact:

Mr Joel Latham, Managing Director and Chief Executive Officer

P: +61 409 840 786

E: joel@incannex.com.au

About Incannex Healthcare Limited (ASX: IHL)

Incannex Healthcare Limited (IHL.ASX) is developing unique medicinal cannabis products for the treatment of Obstructive Sleep Apnoea (OSA), Traumatic Brain Injury (TBI)/Concussion, Acute Respiratory Distress Syndrome (ARDS) and Temporomandibular Joint Disorder (TMD). FDA registration, where being sought, is subject to clinical success.

Each indication represents major global markets and currently have no existing registered pharmacotherapy (drug) treatment, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profiles in clinical trials.

There is an established body of research validating the hypothesis for the cannabinoids being used in Incannex’s chosen therapeutic areas and IHL has a strong patent filing strategy (as announced “IHL files cannabinoid patent over IHL-216A for TBI” 04th October, 2019 and “IHL Files Patent over IHL-42X for OSA” 06th of December, 2019) as it develops its products in conjunction with its medical advisory board.

Further to its clinical programs, Incannex has its Australian license to import, export and distribute medicinal cannabis products and has launched a line of cannabinoid oil products. The cannabis-based oils are sold under Incannex’s product supply and distribution agreement with Cannvalate Pty Ltd, which is the largest network of cannabis medicine prescribers in Australia and a major shareholder of IHL.

Investors: investors@incannex.com.au

For personal use only